JP2002519412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002519412A5 JP2002519412A5 JP2000558081A JP2000558081A JP2002519412A5 JP 2002519412 A5 JP2002519412 A5 JP 2002519412A5 JP 2000558081 A JP2000558081 A JP 2000558081A JP 2000558081 A JP2000558081 A JP 2000558081A JP 2002519412 A5 JP2002519412 A5 JP 2002519412A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound according
- compound
- bis
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 2
- 239000004914 cyclooctane Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- UNTNYPRAGVHVGR-UHFFFAOYSA-N 1-[2-(2-aminobenzimidazol-1-yl)ethyl]benzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1CCN1C2=CC=CC=C2N=C1N UNTNYPRAGVHVGR-UHFFFAOYSA-N 0.000 description 1
- AGJIIBVLGWZMJT-UHFFFAOYSA-N 1-[6-(2-aminobenzimidazol-1-yl)hexyl]benzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1CCCCCCN1C2=CC=CC=C2N=C1N AGJIIBVLGWZMJT-UHFFFAOYSA-N 0.000 description 1
- QWXPDIIFGNWXIH-UHFFFAOYSA-N 1-[[3-[(2-aminobenzimidazol-1-yl)methyl]cyclohexyl]methyl]benzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1CC(C1)CCCC1CN1C2=CC=CC=C2N=C1N QWXPDIIFGNWXIH-UHFFFAOYSA-N 0.000 description 1
- IDNCOFZEILPEHF-UHFFFAOYSA-N 1-cyclooctylbenzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1C1CCCCCCC1 IDNCOFZEILPEHF-UHFFFAOYSA-N 0.000 description 1
- LHASZEBEQGPCFM-CJFMBICVSA-N 2-amino-4-[(1r)-1-[[(6r)-6-[(5-chloro-2-methoxyphenyl)methyl]-7-oxo-3-(phenoxyamino)-5,6-dihydro-2h-1,4-diazepine-1-carbonyl]amino]propyl]benzoic acid Chemical compound C([C@@H]1CNC(CN(C1=O)C(=O)N[C@H](CC)C=1C=C(N)C(C(O)=O)=CC=1)=NOC=1C=CC=CC=1)C1=CC(Cl)=CC=C1OC LHASZEBEQGPCFM-CJFMBICVSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 206010048994 Bladder spasm Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229940125801 compound 7f Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- -1 decamethylene, octamethylene, hexamethylene, dimethylene Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK199800865 | 1998-07-02 | ||
| DKPA199800865 | 1998-07-02 | ||
| PCT/DK1999/000378 WO2000001676A1 (en) | 1998-07-02 | 1999-07-01 | Potassium channel blocking agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002519412A JP2002519412A (ja) | 2002-07-02 |
| JP2002519412A5 true JP2002519412A5 (https=) | 2006-07-27 |
Family
ID=8098413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000558081A Pending JP2002519412A (ja) | 1998-07-02 | 1999-07-01 | カリウムチャンネル遮断剤 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1091942B1 (https=) |
| JP (1) | JP2002519412A (https=) |
| AT (1) | ATE292120T1 (https=) |
| AU (1) | AU4768999A (https=) |
| DE (1) | DE69924493T2 (https=) |
| WO (1) | WO2000001676A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003516309A (ja) | 1999-02-18 | 2003-05-13 | 株式会社アールテック・ウエノ | 涙液分泌障害を除く外分泌障害処置剤 |
| BR0010655A (pt) * | 1999-03-24 | 2002-02-13 | Anormed Inc | Compostos heterocìclicos para ligação ao receptor de quimiocina |
| WO2001002406A1 (en) * | 1999-06-29 | 2001-01-11 | Neurosearch A/S | Potassium channel blocking agents |
| FR2810318B1 (fr) * | 2000-06-15 | 2005-09-23 | Laurent Galey | Derives de diamano-phenothiazine |
| JP4505957B2 (ja) * | 2000-06-27 | 2010-07-21 | ダイキン工業株式会社 | 架橋用エラストマー組成物 |
| EP1394152A4 (en) | 2001-04-19 | 2005-02-02 | Eisai Co Ltd | 2-IMINOIMIDAZOLE DERIVATIVES (1) |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| EP1465609A2 (en) * | 2001-11-07 | 2004-10-13 | Medical Research Council | Modulation of dopaminergic neurons |
| KR100875362B1 (ko) * | 2002-02-05 | 2008-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
| JP2005530763A (ja) * | 2002-05-13 | 2005-10-13 | アイシーエージェン，インコーポレイティド | カリウム・チャネル調節物質としてのビス−ベンズイミダゾール及び関連化合物 |
| AU2003297597A1 (en) * | 2002-11-26 | 2004-06-18 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antibacterials |
| TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| CN100439336C (zh) | 2003-02-19 | 2008-12-03 | 卫材R&D管理有限公司 | 制备环状苯甲脒衍生物的方法 |
| DE10342503A1 (de) * | 2003-09-12 | 2005-04-14 | Merck Patent Gmbh | Benzyl-Benzimidazolylderivate |
| EP1711496A4 (en) | 2004-01-28 | 2009-02-11 | Smithkline Beecham Corp | THIAZOLE COMPOUNDS |
| AU2005268782A1 (en) * | 2004-08-05 | 2006-02-09 | Neurosearch A/S | 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| CN101083985A (zh) * | 2004-09-21 | 2007-12-05 | 幸讬制药公司 | 用于炎症及免疫相关用途的化合物 |
| US7842817B2 (en) | 2005-01-11 | 2010-11-30 | Neurosearch A/S | 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| WO2006089168A2 (en) | 2005-02-18 | 2006-08-24 | Cornell Research Foundation, Inc. | Methods for modulating ion channels |
| WO2008003752A1 (en) * | 2006-07-07 | 2008-01-10 | Neurosearch A/S | 2 -amino benzimidazole derivatives and their use as modulators of small - conductance calcium -act ivated potassium channels |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| WO2008021337A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Oxazinan-2-one derivatives useful as pr modulators |
| WO2008021309A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Imidazolidin-2-one derivatives useful as pr modulators |
| US7649007B2 (en) | 2006-08-15 | 2010-01-19 | Wyeth Llc | Oxazolidine derivatives as PR modulators |
| WO2011018894A1 (en) * | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| KR102811543B1 (ko) | 2019-10-16 | 2025-05-23 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 다환 화합물 |
| CN111777560B (zh) * | 2020-07-24 | 2021-11-30 | 贵州民族大学 | 一种氨基苯并咪唑类化合物及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4004016A (en) * | 1975-08-11 | 1977-01-18 | E. R. Squibb & Sons, Inc. | Amino-benzimidazole derivatives |
| US5190976A (en) * | 1986-07-10 | 1993-03-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
| WO1991018868A1 (en) * | 1990-05-25 | 1991-12-12 | STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY | Substituted guanidines having high binding to the sigma receptor and the use thereof |
| ES2113898T3 (es) * | 1991-06-24 | 1998-05-16 | Neurosearch As | Compuestos de imidazol, su fabricacion y utilizacion. |
| US5314903A (en) * | 1991-12-03 | 1994-05-24 | Neurosearch A/S | Benzimidazole compounds useful as calcium channel blockers |
| DK154092D0 (da) * | 1992-12-23 | 1992-12-23 | Neurosearch As | Imidazolforbindelser, deres fremstilling og anvendelse |
| DK41193D0 (da) * | 1993-04-07 | 1993-04-07 | Neurosearch As | Ionkanalaabnere |
-
1999
- 1999-07-01 AT AT99931019T patent/ATE292120T1/de not_active IP Right Cessation
- 1999-07-01 AU AU47689/99A patent/AU4768999A/en not_active Abandoned
- 1999-07-01 DE DE69924493T patent/DE69924493T2/de not_active Expired - Lifetime
- 1999-07-01 EP EP99931019A patent/EP1091942B1/en not_active Expired - Lifetime
- 1999-07-01 JP JP2000558081A patent/JP2002519412A/ja active Pending
- 1999-07-01 WO PCT/DK1999/000378 patent/WO2000001676A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002519412A5 (https=) | ||
| JP2002531552A5 (https=) | ||
| JP2008520745A5 (https=) | ||
| US7759126B2 (en) | Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for amplification (or PCR) analysis | |
| US6548652B2 (en) | Attachment of oligonucleotides to solid supports through schiff base type linkages for capture and detection of nucleic acids | |
| US20160265048A1 (en) | Chemically cleavable 3'-o-allyl-dntp-allyl-fluorophore fluorescent nucleotide analogues and related methods | |
| US10851407B2 (en) | Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor | |
| Dálaigh et al. | Kinetic resolution of sec-alcohols using a new class of readily assembled (S)-proline-derived 4-(pyrrolidino)-pyridine analogues | |
| US20230105320A1 (en) | Carborhodamine compounds and methods of preparation thereof | |
| WO1998009949A1 (en) | Novel acetamide derivatives and protease inhibitors | |
| KR20080065668A (ko) | (3ｒ,5ｒ)-7-[2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-[(4-히드록시 메틸 페닐아미노)카르보닐]-피롤-1-일]-3,5-디히드록시 헵탄산 헤미칼슘염의 제조 방법 | |
| CA2492342C (en) | Novel bio-active pyrimidine derivatives | |
| JP2008539299A5 (https=) | ||
| US20010044530A1 (en) | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | |
| JP2002531539A5 (https=) | ||
| CN101223132A (zh) | 制备磺酰胺衍生物的方法 | |
| WO1997009318A1 (en) | Pyrimidine derivatives | |
| JP3775911B2 (ja) | ポリカーボネート重合体及びその製造方法 | |
| Qiao et al. | Covalently Cross‐Linked Watson–Crick Base Pair Models | |
| JP2009222635A (ja) | 核酸検出方法 | |
| CN114957341B (zh) | 一种螺吡喃铂配合物及其制备和在光控手光开关材料上的应用 | |
| Hsieh et al. | Synthesis of (R)-and (S)-Fmoc-protected diethylene glycol gamma PNA monomers with high optical purity | |
| Jacquemard et al. | Synthesis of diphenylcarbazoles as cytotoxic DNA binding agents | |
| JP5542666B2 (ja) | ジアゾ及びニトロ官能基を担持するマーキング試薬、当該試薬の合成する方法及び生体分子を検出する方法 | |
| CN113444107B (zh) | 琥珀酰亚胺螺稠合磺内酰胺类化合物的合成方法及抗癌活性 |